Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Atea Pharmaceuticals Inc(AVIR)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for AVIR
09/25/2026: AVIR (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Atea Pharmaceuticals is a clinical-stage biotechnology company developing oral antiviral treatments using a proprietary nucleotide prodrug platform. The company's main strength lies in its specialized scientific expertise and its focus on the HCV market. Its primary growth opportunity centers on the successful clinical development and eventual commercialization of its lead candidate, bemnifosbuvir. However, the company faces significant risks including clinical trial execution, high cash burn, and competition from large, established pharmaceutical incumbents. The stock is best suited for risk-tolerant investors looking for long-term clinical upside, and market participants should monitor clinical data readouts and potential licensing or partnership developments closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company represents a high-risk, high-reward play on clinical development rather than established revenue growth. |
| Momentum investor | Weak fit | Momentum is generally tied to positive clinical trial catalysts rather than sustained price trends. |
| Value investor | Weak fit | As a pre-revenue clinical-stage firm, traditional valuation metrics are not applicable. |
| Dividend investor | Weak fit | The company is in an intensive capital-spend phase and does not pay dividends. |
| Low-risk investor | Weak fit | Clinical-stage biotechnology stocks carry inherent high volatility and binary event risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is highly sensitive to binary clinical data outcomes. |
| Valuation risk | High | Valuation is speculative and dependent on future clinical milestones. |
| Competition risk (Antiviral market) | High | The company faces entrenched incumbents with substantial resources. |
| Business quality | Medium | The business is early-stage, lacking the stability of commercialized operations. |
| Dividend income | Low / none | No capital return program exists for shareholders. |
| Execution risk | High | Successful clinical execution is required to realize any future value. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 8.51% | Avg. Invested days 31 | Today’s Advisory WEAK BUY |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 414.66M USD | Price to earnings Ratio - | 1Y Target Price 9.42 |
Price to earnings Ratio - | 1Y Target Price 9.42 | ||
Volume (30-day avg) 257.9K shares | Beta 0.28 | 52 Weeks Range 2.78 - 6.45 | Updated Date 09/26/2026 |
52 Weeks Range 2.78 - 6.45 | Updated Date 09/26/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.08 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Drug Development | Research and development of oral antiviral therapeutics. | The company currently spends money to develop drugs rather than earning revenue. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 204.84M | Price to Sales(TTM) 1.55 |
Enterprise Value 204.84M | Price to Sales(TTM) 1.55 | ||
Enterprise Value to Revenue 58.97 | Enterprise Value to EBITDA -260.47 | Shares Outstanding 80.20M | Shares Floating 60.34M |
Shares Outstanding 80.20M | Shares Floating 60.34M | ||
Percent Insiders 13.37 | Percent Institutions 79.14 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Atea Pharmaceuticals Inc
Exchange NASDAQ | Headquarters Boston, MA, United States | ||
IPO Launch date 2020-10-30 | Founder, Chairman, CEO & President Dr. Jean-Pierre Sommadossi Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 55 | Website https://ateapharma.com |
Full time employees 55 | Website https://ateapharma.com | ||
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.